Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176362635> ?p ?o ?g. }
- W3176362635 endingPage "LB157" @default.
- W3176362635 startingPage "LB157" @default.
- W3176362635 abstract "Abstract In the tumor microenvironment, ATP released by dying cells is converted to adenosine, a well-established potent suppressor of immune cell activity. The immune suppressive function of extracellular adenosine is mediated through two G-protein coupled receptors known as A2A and A2B. Both receptors are expressed on many types of immune cells. While A2B has traditionally been considered of less relevance compared to A2A due to lower affinity to its ligand adenosine, recent evidence suggests a specific role of A2B in immune suppressive myeloid cells in cancer. To determine whether a small molecule inhibitor which blocks both adenosine receptors on immune cells can be used as an immunotherapy to enhance anti-tumor immune responses, we initiated a discovery campaign to identify dual antagonist inhibitors of A2A and A2B. INCB106385 is a potent, selective and orally bioavailable dual antagonist of A2A and A2B receptors. In vitro, INCB106385 potently binds to both A2A and A2B receptors in the single-digit nanomolar range and antagonizes downstream signaling as measured by cAMP production in A2A and A2B expressing cells. In functional studies, INCB106385, in the presence of 50μM AMP, restores effector T cell activity as measured by interferon gamma (IFNγ) production. In vivo, INCB106385 inhibited both the downstream effector pCREB and tumor growth in CT26 and B16-F10 syngeneic tumor models. Furthermore, in in vitro and in vivo combination studies, INCB106385 and anti-PD-1/PD-L1 CPIs demonstrated an increase in T cell function and anti-tumor activity compared to the single agent treatment groups. These data suggests that inhibition of the adenosine pathway is non-redundant to current checkpoint inhibitor therapies and can be an effective combination strategy to enhance anti-tumor immune activities. In summary, the data presented in this study demonstrate that INCB106385 is a potent, selective and orally bioavailable A2A/A2B dual antagonist that can overcome the immune-suppressive effects of high levels of adenosine in the tumor microenvironment. INCB106385 can promote anti-tumor immunity as a monotherapy and in combination with anti-PD-1/PD-L1 treatment. Citation Format: Hui Wang, Alexandra Alexandra, Michael Hansbury, Jennifer Mason, Jennifer Harris, Christina Stevens, Christopher Maddage, Xiaodi Ren, Mingming Gao, Kerri Kurzeja-Lipinski, Gengjie Yang, Patricia Conlen, Kristine Stump, Patricia Feldman, Pramod Thekkat, Luping Lin, Maryanne Covington, Swamy Yeleswaram, Chao Qi, Xiaozhao Wang, Wenqing Yao, Sunkyu Kim, Susan Wee, Yingnan Chen, Holly Koblish. Discovery and characterization of INCB106385: a novel A2A/A2B adenosine receptor antagonist, as a cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB157." @default.
- W3176362635 created "2021-07-05" @default.
- W3176362635 creator A5000577175 @default.
- W3176362635 creator A5000850685 @default.
- W3176362635 creator A5018886805 @default.
- W3176362635 creator A5023090545 @default.
- W3176362635 creator A5026189827 @default.
- W3176362635 creator A5031789754 @default.
- W3176362635 creator A5038610155 @default.
- W3176362635 creator A5041230347 @default.
- W3176362635 creator A5047463448 @default.
- W3176362635 creator A5048475974 @default.
- W3176362635 creator A5061208308 @default.
- W3176362635 creator A5063987949 @default.
- W3176362635 creator A5065651204 @default.
- W3176362635 creator A5068500323 @default.
- W3176362635 creator A5072989379 @default.
- W3176362635 creator A5076394182 @default.
- W3176362635 creator A5076797095 @default.
- W3176362635 creator A5077094654 @default.
- W3176362635 creator A5081541931 @default.
- W3176362635 creator A5084225119 @default.
- W3176362635 creator A5084386900 @default.
- W3176362635 creator A5087078289 @default.
- W3176362635 creator A5088149019 @default.
- W3176362635 creator A5088594721 @default.
- W3176362635 creator A5090366405 @default.
- W3176362635 date "2021-07-01" @default.
- W3176362635 modified "2023-09-27" @default.
- W3176362635 title "Abstract LB157: Discovery and characterization of INCB106385: a novel A2A/A2B adenosine receptor antagonist, as a cancer immunotherapy" @default.
- W3176362635 doi "https://doi.org/10.1158/1538-7445.am2021-lb157" @default.
- W3176362635 hasPublicationYear "2021" @default.
- W3176362635 type Work @default.
- W3176362635 sameAs 3176362635 @default.
- W3176362635 citedByCount "1" @default.
- W3176362635 countsByYear W31763626352022 @default.
- W3176362635 crossrefType "journal-article" @default.
- W3176362635 hasAuthorship W3176362635A5000577175 @default.
- W3176362635 hasAuthorship W3176362635A5000850685 @default.
- W3176362635 hasAuthorship W3176362635A5018886805 @default.
- W3176362635 hasAuthorship W3176362635A5023090545 @default.
- W3176362635 hasAuthorship W3176362635A5026189827 @default.
- W3176362635 hasAuthorship W3176362635A5031789754 @default.
- W3176362635 hasAuthorship W3176362635A5038610155 @default.
- W3176362635 hasAuthorship W3176362635A5041230347 @default.
- W3176362635 hasAuthorship W3176362635A5047463448 @default.
- W3176362635 hasAuthorship W3176362635A5048475974 @default.
- W3176362635 hasAuthorship W3176362635A5061208308 @default.
- W3176362635 hasAuthorship W3176362635A5063987949 @default.
- W3176362635 hasAuthorship W3176362635A5065651204 @default.
- W3176362635 hasAuthorship W3176362635A5068500323 @default.
- W3176362635 hasAuthorship W3176362635A5072989379 @default.
- W3176362635 hasAuthorship W3176362635A5076394182 @default.
- W3176362635 hasAuthorship W3176362635A5076797095 @default.
- W3176362635 hasAuthorship W3176362635A5077094654 @default.
- W3176362635 hasAuthorship W3176362635A5081541931 @default.
- W3176362635 hasAuthorship W3176362635A5084225119 @default.
- W3176362635 hasAuthorship W3176362635A5084386900 @default.
- W3176362635 hasAuthorship W3176362635A5087078289 @default.
- W3176362635 hasAuthorship W3176362635A5088149019 @default.
- W3176362635 hasAuthorship W3176362635A5088594721 @default.
- W3176362635 hasAuthorship W3176362635A5090366405 @default.
- W3176362635 hasConcept C134018914 @default.
- W3176362635 hasConcept C170493617 @default.
- W3176362635 hasConcept C185592680 @default.
- W3176362635 hasConcept C203014093 @default.
- W3176362635 hasConcept C2776107976 @default.
- W3176362635 hasConcept C2776991684 @default.
- W3176362635 hasConcept C2777701055 @default.
- W3176362635 hasConcept C2778938600 @default.
- W3176362635 hasConcept C2780674031 @default.
- W3176362635 hasConcept C502942594 @default.
- W3176362635 hasConcept C55493867 @default.
- W3176362635 hasConcept C67907053 @default.
- W3176362635 hasConcept C86803240 @default.
- W3176362635 hasConcept C8891405 @default.
- W3176362635 hasConcept C95444343 @default.
- W3176362635 hasConcept C98274493 @default.
- W3176362635 hasConceptScore W3176362635C134018914 @default.
- W3176362635 hasConceptScore W3176362635C170493617 @default.
- W3176362635 hasConceptScore W3176362635C185592680 @default.
- W3176362635 hasConceptScore W3176362635C203014093 @default.
- W3176362635 hasConceptScore W3176362635C2776107976 @default.
- W3176362635 hasConceptScore W3176362635C2776991684 @default.
- W3176362635 hasConceptScore W3176362635C2777701055 @default.
- W3176362635 hasConceptScore W3176362635C2778938600 @default.
- W3176362635 hasConceptScore W3176362635C2780674031 @default.
- W3176362635 hasConceptScore W3176362635C502942594 @default.
- W3176362635 hasConceptScore W3176362635C55493867 @default.
- W3176362635 hasConceptScore W3176362635C67907053 @default.
- W3176362635 hasConceptScore W3176362635C86803240 @default.
- W3176362635 hasConceptScore W3176362635C8891405 @default.
- W3176362635 hasConceptScore W3176362635C95444343 @default.
- W3176362635 hasConceptScore W3176362635C98274493 @default.
- W3176362635 hasIssue "13_Supplement" @default.
- W3176362635 hasLocation W31763626351 @default.
- W3176362635 hasOpenAccess W3176362635 @default.
- W3176362635 hasPrimaryLocation W31763626351 @default.